Description

Combretastatin is a potent, naturally-derived stilbenoid compound that functions as a vascular disrupting agent (VDA). Its primary value lies in its ability to selectively target and destabilize the cytoskeleton of proliferating endothelial cells in tumor vasculature, leading to rapid tumor blood vessel shutdown. This mechanism makes it a critical compound of interest in oncology research and pharmaceutical development. Key industries requiring this material include pharmaceutical R&D, biotechnology, and academic research institutions focused on developing novel anti-cancer therapeutics and studying tumor biology.

Application

• Pharmaceutical Intermediate: Serves as a key starting material or reference standard in the synthesis and development of novel anti-cancer drugs and vascular-targeting agents.
• Biomedical Research: Used extensively in in vitro and in vivo studies to investigate mechanisms of angiogenesis inhibition and tumor vasculature collapse.
• Preclinical Development: Employed as a benchmark compound for evaluating the efficacy and pharmacokinetics of new vascular disrupting agents in animal models.
• Mechanistic Studies: A vital tool for studying tubulin polymerization dynamics, cytoskeletal integrity, and endothelial cell biology.
• Reference Standard: Utilized in analytical laboratories for method development, validation, and quality control of related pharmaceutical products.
• Drug Discovery Screening: Acts as a positive control in high-throughput screening assays designed to identify new compounds with anti-angiogenic or vascular disrupting properties.

Basic Information

Item	Detail
Product Name	Combretastatin
CAS No.	82855-09-2
Molecular Formula	C18H20O5
Molecular Weight	316.35 g/mol
Synonyms	Combretastatin A-4; (Z)-Combretastatin A4; CA-4; (Z)-1-(3,4,5-Trimethoxyphenyl)-2-(3-hydroxy-4-methoxyphenyl)ethene; NSC 64087; Phenstatin precursor; Vascular Disrupting Agent CA4; Stilbenoid CA4
EINECS	Contact for details

Quality Control

Our Combretastatin is manufactured under strict quality management systems to ensure batch-to-batch consistency and high purity suitable for research and development applications. All materials are accompanied by a comprehensive Certificate of Analysis (COA) detailing identity, purity, and impurity profiles as determined by advanced analytical techniques including HPLC, NMR, and MS. We adhere to cGMP guidelines where applicable for the production of pharmaceutical intermediates.

Storage

Preserve in a tightly closed container, protected from light. Store at controlled room temperature, typically between 15-25°C, in a cool, dry, and well-ventilated area. Keep the container tightly sealed to protect from moisture.

Specification

Item	Specification
Appearance	White to off-white powder
Identification (HPLC)	Conforms to reference standard
Identification (IR)	Conforms to structure
Purity (HPLC)	≥ 98.0%
Water Content (KF)	≤ 0.5%
Residue on Ignition	≤ 0.1%
Heavy Metals	≤ 10 ppm
Specific Rotation	Contact for details

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.